Our recently reported estimates of the performance of antenatal reflex DNA screening for Down's syndrome 1 were based on reflexing a proportion of women to DNA screening according to their risk of having an affected pregnancy using a first trimester Combined test (free b-human chorionic gonatrophin [hCG], pregnancy associated plasma protein-A, and nuchal translucency with maternal age). We have been asked (private communication) for corresponding estimates using total instead of free b-hCG in the Combined test. Table 1 shows detection and false-positive rates according to the proportion of women reflexed, together with the first trimester risk cutoff required to achieve the specified reflexing proportions according to the week of pregnancy (11, 12, or 13 completed weeks) . Table 2 shows, for measurements at 11, 12, and 13 weeks of pregnancy, the reflexing proportion according to the Combined test risk cut-off. The results are similar to those using free b-hCG in the Combined 
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